Clinical trials: Escherichia Coli Infections
Infection, Achlorhydria
Clinical Experiment of Helicobacter Pylori Transmission
The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli.
- Trial name
- NCT00550368
- Testing
- Biological intervention: Enteropathogenic E. coli
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Urinary Tract Infection
Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study
This study is a prospective pilot clinical trial investigating the use of urinary catheters coated with benign E. coli in geriatric subjects.
- Trial name
- NCT00554996
- Testing
- E. coli 83972 coated urinary catheter
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Department of Veterans Affairs
Molybdenum Cofactor Deficiency, Type A
Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP
This study will include a screening period, a 6-month treatment period, followed by long-term extension period expected to last approximately 72 months.
- Trial name
- NCT02047461
- Testing
- ORGN001 (formerly ALXN1101)
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 8 people
- Sponsor
- Origin Biosciences
Escherichia Coli Infection
Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea
The purpose of the study is to determine if immunization with a chimeric E. coli protein, dsc14CfaE-sCT2/LTB5, is safe and immunogenic when administered by vaccination under the skin.
- Trial name
- NCT01644565
- Testing
- Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Urinary Tract Infection
The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
The SCOUT study is a multi-center, centrally randomized, double-blind, placebo-controlled non-inferiority clinical trial. 746 participants will be enrolled over a 4.5 year period.
- Trial name
- NCT01595529
- Testing
- Cefixime, Cephalexin, Trimethoprim/Sulfamethoxazole
- Where
- United States
- Volunteers
- 717 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia…
- Trial name
- NCT04899336
- Testing
- ExPEC9V
- Where
- 374 sites in United States, Australia and 19 more
- Volunteers
- 17,797 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diarrhea, Travelers Diarrhea
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli…
- Conditions
- Diarrhea, Travelers Diarrhea, Infectious Diarrhea
- Trial name
- NCT05933525
- Testing
- Travelan
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Immuron Ltd.
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
- Trial name
- NCT03576183
- Testing
- VLA1701, Challenge Strain
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Gastroenteritis Escherichia Coli, Immunisation
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135…
- Trial name
- NCT03548064
- Testing
- Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Where
- 2 sites in United States, Bangladesh
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody…
- Trial name
- Engage (NCT06134804)
- Testing
- ExPEC9V, HD quadrivalent influenza vaccine
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diarrhea
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by intramuscular (IM) injection.
- Trial name
- NCT03404674
- Testing
- CssBA, dmLT
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PATH
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.
- Trial name
- NCT02964910
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.
- Trial name
- NCT04634513
- Testing
- strain CVD 1208S-122
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Acute Urinary Tract Infection, Urinary Tract Infection
Corticosteroids for Children With Febrile Urinary Tract Infections
In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.
- Trial name
- STARRS (NCT01391793)
- Testing
- Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 546 people
- Sponsor
- Nader Shaikh
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger…
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Trial name
- NCT00671034
- Testing
- Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine
- Where
- 27 sites in United States
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteer
Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A
The purpose of this study is to determine the safe and optimal dose and regimen (fasting duration) for administering the challenge ETEC strain B7A, a CS6 expressing ETEC strain.
- Trial name
- NCT02773446
- Testing
- ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Extraintestinal Pathogenic Escherichia Coli Prevention
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health
The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of 3 different doses of ExPEC10V and to select the optimal dose for further clinical development (Cohort 1).
- Trial name
- NCT03819049
- Testing
- ExPEC10V, ExPEC4V, Prevnar 13
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 836 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Urinary Tract Infection
Cranberry for UTI Prevention in Residents of Long Term Care Facilities
Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the health care industry over 1 billion dollars annually.
- Trial name
- PACS (NCT00596635)
- Testing
- Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Yale University
Polio
Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
In this study, the safety and tolerability of inactivated polio vaccine (IPV) co-administered with dmLT will be assessed, as well as whether co-administration of dmLT with IPV enhances mucosal responses compared to those with IPV…
- Trial name
- NCT04232943
- Testing
- Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV)
- Where
- Belgium
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- PATH